PYC Therapeutics (ASX:PYC) logged AU$0.0591 in loss per share for fiscal 2026, compared with a loss of AU$0.1005 a year ago, according to a filing on Aug. 28 after market hours.
For the 12 months ended June 30, revenue was AU$39.7 million versus AU$26.2 million previously, the Australia-listed biotechnology company added.